Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gastrointestinal 2Endocrine 2CNS 2Breast 2Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Carcinoma, Medullary 4Thyroid Neoplasms 3Sarcoma 3Central Nervous System Neoplasms 3Wilms Tumor 2Thyroid Diseases 2Thyroid Cancer, Papillary 2Thoracic Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms by Site 2Neoplasms 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Lung Diseases 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Head and Neck Neoplasms 2Glioma 2Ependymoma 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 5lenvatinib 3cabozantinib 3Sunitinib 3Iodine-131 3trametinib 2selpercatinib 2dabrafenib 2Sorafenib 2Fluorodeoxyglucose F18 2AZD 6244 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2vandetanib 1tremelimumab 1tovorafenib 1tanespimycin 1romidepsin 1pralsetinib 1pembrolizumab 1omipalisib 1durvalumab 1copanlisib 1cediranib 1alectinib 1aflibercept 1Vorinostat 1Vemurafenib 1Thyrotropin Alfa 1Thyroidectomy 1Thyroid (USP) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Thyroid Cancer, Papillary × selpercatinib × Clear all
NCT03157128 2026-04-16

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 24 charts 3 FDA
BreastCNSEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
BreastCNSEndocrineGastrointestinalHead & NeckSarcomaThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Myofibromatosis, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡